ADAP - Adaptimmune Therapeutics plc Stock Trading

Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...

Adaptimmune Therapeutics plc (ADAP) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Juli Miller - Director of Investor Relations Adrian Rawcliffe - Chief Executive Officer Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medic...

Adaptimmune (NASDAQ: ADAP ): Q4 GAAP EPS of -$0.05 beats by $0.27 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...